Wyniki wyszukiwania - Biblioteka Nauki

Ten serwis zostanie wyłączony 2025-02-11.

Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl

Ograniczanie wyników

Znaleziono wyników: 2

Liczba wyników na stronie

Wyniki wyszukiwania

Sortuj według:

Ogranicz wyniki do:

Peptide receptor radionuclide therapy as a tool for the treatment of severe hypoglycemia in patients with primary inoperable insulinoma

100%

Opalińska M. , Sowa-Staszczak A. , Al Maraih I. , Gilis-Januszewska A. , Hubalewska-Dydejczyk A.

Bio-Algorithms and Med-Systems

2021

tom Vol. 17, no. 4

221--226

Objectives: Severe hypoglycemia in a course of inoperable insulinoma may be life-threating and often it is not well controlled, even by high doses of diazoxide requiring second line treatment. Among available methods PRRT is characterized by relatively low toxicity and is connected with favorable antitumor effect. The aim of the study was an evaluation of the PRRT effectiveness in control of hypoglycemia in patients with primary inoperable insulinoma. Methods: Three patients (female with metastatic insulinoma,male with primaryinoperable pancreatic tumor, female with MEN1 syndrome and hepatic metastases) were treated with PRRT due to severe hypoglycemia poorly controlled by diazoxide in course of primary inoperable insulinoma. Results: Patient 1 baseline fasting glucose concentration increased from 2.4 mmol/L [3.30-5.60] to 5.9 mmol/L after PRRT. In patient 2 fasting glucose level 2.30 mmol/L increased after PRRT to 7.0 mmol/L, while baseline insulin level initially 31.15 uU/mL [2.6–24.9] decreased to 15.4 uU/mL. In patients 3, baseline fasting glucose level 2.5 mmol/L increased after PRRT to 7.9 mmol/L, and insulin decreased from 57.9 uU/mL to 6.3 uU/mL. In imaging there was partial response (PR) in patient 1 and 2 and stabilization of the tumor size in patient 3. In patient 2 reduction of tumor infiltration let for curative surgery performed 4 months after PPRT. Conclusions: PRRT may be effective as a first or second line treatment in management of hypoglycemia for patients with hormonally active inoperable insulinoma.

Individual dosimetry and monitoring response to treatment in tandem PRRT with [177Lu/90Y]-DOTA-TATE

51%

Kacperski K. , Budzyńska A. , Kubik A. , Pastusiak P. , Chalewska W. , Lenda-Tracz W. , Borkowska A. , Walecka-Mazur A. , Szczodry A. , Braziewicz J. , Kołodziej M. , Kamiński G. , Dedecjus M. , Długosińska J. , Januszkiewicz-Caulier J. , Hubalewska-Dydejczyk A. , Opalińska M. , Kowalska A. , Mikołajczak R.

Polish Journal of Medical Physics and Engineering

2024

tom Vol. 30, Iss. 4

294--299

Introduction: The Duonen project aims to test the efficacy of tandem PRRT therapy of neuroendocrine tumors with DOTA-TATE labeled with 177Lu and 90Y radionuclides compared to conventional mono-radionuclide therapy using 177Lu with a fixed activity of 7.4 GBq. The paper presents the dosimetric procedure used and preliminary results obtained from the treatment of 40 patients and 113 cycles of therapy. Material and Methods: Dosimetry is performed using the QDose program based on 4 SPECT/CT scans and 5 blood samples taken for bone marrow dosimetry. Calculation of the dose to the kidneys is done by segmenting them on images, fitting the corresponding activity versus time (TAC) curves and calculating the dose using the Voxel-S method. The dose to the red marrow is calculated based on the IDAC2 model using the TAC curve for blood obtained from the measurements (self-dose) and the segmented organs from images (cross-dose). In addition, the time-integrated activity coefficients of activity in selected tumors or high uptake areas in four consecutive cycles of therapy were calculated for several patients as a measure of response to therapy. Results: Large variability of individual doses to kidneys is observed. The average specific dose for 177Lu was equal to 0.76 Gy/GBq, SD = 0.29 Gy/GBq, and for 90Y: 3.26 Gy/GBq, SD = 1.26 Gy/GBq. With the standard activity equal to 7.4 GBq in the first cycle, the activity in the next cycle could be increased by > 10% in 60% of cases and had to be decreased in 16% of cases. Conclusion: Individual dosimetry is an important part of PRRT, leading to significant dose modifications in subsequent cycles in more than 80% of the cases studied.